"The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for"...
There is no known antidote for JEVTANA overdose. Overdose has resulted from improper preparation [see DOSAGE AND ADMINISTRATION]. Read the entire section DOSAGE AND ADMINISTRATION carefully before mixing or diluting. Complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Overdose has led to fatal outcome.
In case of overdose, the patient should be kept in a specialized unit where vital signs, chemistry and particular functions can be closely monitored. Patients should receive therapeutic G-CSF as soon as possible after discovery of overdose. Other appropriate symptomatic measures should be taken, as needed.
JEVTANA is contraindicated in patients with:
- neutrophil counts of ≤ 1,500/mm³ [see WARNINGS AND PRECAUTIONS]
- history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80 [see WARNINGS AND PRECAUTIONS]
- severe hepatic impairment (total bilirubin > 3 x ULN) [see WARNINGS AND PRECAUTIONS]
Last reviewed on RxList: 7/8/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Jevtana Information
Jevtana - User Reviews
Jevtana User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.